{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T08:55:31Z","timestamp":1790931331968,"version":"4.1.0"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Testicular germ cell tumours (TGCTs) are the most common malignancy in young adult males. After chemotherapy, the evaluation of residual masses is critical. However, the current standard imaging modality, [\n                      <jats:sup>18<\/jats:sup>\n                      F]-FDG PET, has limited specificity\u2014particularly in distinguishing viable tumour from necrosis or mature teratoma. This limitation often leads to unnecessary surgery or misinterpretation of treatment response.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>This systematic review aims to explore and evaluate novel PET tracers that could improve diagnostic accuracy in TGCTs, especially in post-chemotherapy settings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A comprehensive literature search was conducted on PubMed and Scopus through December 2025, using terms including \u201ctesticular,\u201d \u201cgerm cell tumour,\u201d \u201cPET scan,\u201d and \u201cnovel.\u201d Studies focusing solely on [\n                      <jats:sup>18<\/jats:sup>\n                      F]-FDG were excluded. Preclinical studies, case reports, and clinical trials investigating alternative PET tracers or relevant molecular targets (e.g., ghrelin, claudin-6) were included. The quality of selected articles was assessed by using CASP for the qualitative research.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 17 studies met the inclusion criteria. Emerging PET tracers evaluated include [\n                      <jats:sup>18<\/jats:sup>\n                      F]-FLT, FAPI, \u03b1v\u03b23-integrin-targeted agents, [\n                      <jats:sup>18<\/jats:sup>\n                      F]-fluciclovine, PSMA-targeted tracers, and those based on ghrelin and claudin-6. Among these, \u03b1v\u03b23-targeted imaging has shown promising preclinical results in differentiating mature teratoma from necrosis. Ghrelin receptor tracers appear promising due to their high expression in TGCTs, although they remain in preclinical development. Claudin-6, a tight-junction protein, is highly expressed in most TGCT histologies and may be a viable molecular target, as supported by early-phase clinical trials.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Novel PET tracers represent a promising avenue to refine TGCT management. \u03b1v\u03b23-integrin and ghrelin-based tracers are particularly noteworthy for their potential to guide decision-making after chemotherapy. However, further clinical validation is required before routine implementation. These innovations could significantly reduce overtreatment and enhance personalized care in TGCT patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00259-026-08044-5","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T06:31:02Z","timestamp":1782973862000},"page":"6762-6774","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Novel PET tracers to distinguish the nature of residual masses after the completion of chemotherapy in metastatic testicular germ cell tumours: A systematic review"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-9708-3629","authenticated-orcid":false,"given":"Alessandro","family":"Bertocchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1811-7050","authenticated-orcid":false,"given":"Fabio","family":"De Vincenzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9864-8814","authenticated-orcid":false,"given":"Matteo","family":"Perrino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-6968-270X","authenticated-orcid":false,"given":"Nadia","family":"Cordua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9150-4367","authenticated-orcid":false,"given":"Priscilla","family":"Guglielmo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Aliprandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4362-9892","authenticated-orcid":false,"given":"Luigi Giovanni","family":"Cecchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-1278-9223","authenticated-orcid":false,"given":"Antonio","family":"Federico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Panzardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1709-9492","authenticated-orcid":false,"given":"Armando","family":"Santoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5955-9488","authenticated-orcid":false,"given":"Laura","family":"Evangelista","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2274-1702","authenticated-orcid":false,"given":"Paolo Andrea","family":"Zucali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,2]]},"reference":[{"key":"8044_CR1","doi-asserted-by":"publisher","unstructured":"Sung H, Global Cancer Statistics. 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209\u201349. https:\/\/doi.org\/10.3322\/caac.21660","DOI":"10.3322\/caac.21660"},{"issue":"3","key":"8044_CR2","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1002\/ijc.32810","volume":"147","author":"A Znaor","year":"2020","unstructured":"Znaor A, et al. Testicular cancer incidence predictions in Europe 2010\u20132035: A rising burden despite population ageing. Int J Cancer. 2020;147(3):820\u20138. https:\/\/doi.org\/10.1002\/ijc.32810.","journal-title":"Int J Cancer"},{"issue":"5","key":"8044_CR3","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.eururo.2022.06.016","volume":"82","author":"H Moch","year":"2022","unstructured":"Moch H, et al. The 2022 World Health Organization Classification of Tumours of the Urinary System and Male Genital Organs\u2014Part A: Renal, Penile, and Testicular Tumours. Eur Urol. 2022;82(5):458\u201368. https:\/\/doi.org\/10.1016\/j.eururo.2022.06.016.","journal-title":"Eur Urol"},{"key":"8044_CR4","unstructured":"Heidenreich A et al. EAU Guidelines on Testicular Cancer 2026,., 2026, Arnhem, The Netherlands. [Online]. Available: https:\/\/uroweb.org\/guidelines\/testicular-cancer"},{"issue":"4","key":"8044_CR5","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.annonc.2022.01.002","volume":"33","author":"J Oldenburg","year":"2022","unstructured":"Oldenburg J, et al. Testicular seminoma and non-seminoma: ESMO-EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up \u2606. Ann Oncol. 2022;33(4):362\u201375. https:\/\/doi.org\/10.1016\/j.annonc.2022.01.002.","journal-title":"Ann Oncol"},{"key":"8044_CR6","doi-asserted-by":"publisher","unstructured":"Cathomas R, et al. Questioning the Value of Fluorodeoxyglucose Positron Emission Tomography for Residual Lesions After Chemotherapy for Metastatic Seminoma: Results of an International Global Germ Cell Cancer Group Registry. J Clin Oncol. 2018;1800210:JCO. https:\/\/doi.org\/10.1200\/JCO.18.00210.","DOI":"10.1200\/JCO.18.00210"},{"issue":"2","key":"8044_CR7","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1200\/JCO.1996.14.2.454","volume":"14","author":"HS Puc","year":"1996","unstructured":"Puc HS, et al. Management of residual mass in advanced seminoma: results and recommendations from the Memorial Sloan-Kettering Cancer Center. J Clin Oncol. 1996;14(2):454\u201360. https:\/\/doi.org\/10.1200\/JCO.1996.14.2.454.","journal-title":"J Clin Oncol"},{"issue":"1","key":"8044_CR8","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1023\/a:1008241904019","volume":"8","author":"A Horwich","year":"1997","unstructured":"Horwich A, et al. Residual mass following chemotherapy of seminoma. Ann Oncol. 1997;8(1):37\u201340. https:\/\/doi.org\/10.1023\/a:1008241904019.","journal-title":"Ann Oncol"},{"issue":"3","key":"8044_CR9","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/S0022-5347(01)65065-1","volume":"157","author":"HW Herr","year":"1997","unstructured":"Herr HW, et al. Surgery for a post-chemotherapy residual mass in seminoma. J Urol. 1997;157(3):860\u20132. https:\/\/doi.org\/10.1016\/S0022-5347(01)65065-1.","journal-title":"J Urol"},{"issue":"2","key":"8044_CR10","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.eururo.2007.10.033","volume":"53","author":"A Heidenreich","year":"2008","unstructured":"Heidenreich A, Th\u00fcer D, Polyakov S. Postchemotherapy Retroperitoneal Lymph Node Dissection in Advanced Germ Cell Tumours of the Testis. Eur Urol. 2008;53(2):260\u201374. https:\/\/doi.org\/10.1016\/j.eururo.2007.10.033.","journal-title":"Eur Urol"},{"issue":"36","key":"8044_CR11","doi-asserted-by":"publisher","first-page":"5930","DOI":"10.1200\/JCO.2008.17.1157","volume":"26","author":"K Oechsle","year":"2008","unstructured":"Oechsle K, et al. [18F]Fluorodeoxyglucose Positron Emission Tomography in Nonseminomatous Germ Cell Tumors After Chemotherapy: The German Multicenter Positron Emission Tomography Study Group. J Clin Oncol. 2008;26(36):5930\u20135. https:\/\/doi.org\/10.1200\/JCO.2008.17.1157.","journal-title":"J Clin Oncol"},{"issue":"9","key":"8044_CR12","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1002\/cncr.10494","volume":"94","author":"C Kollmannsberger","year":"2002","unstructured":"Kollmannsberger C, et al. Prospective comparison of [18F]fluorodeoxyglucose positron emission tomography with conventional assessment by computed tomography scans and serum tumor markers for the evaluation of residual masses in patients with nonseminomatous germ cell carcinoma. Cancer. 2002;94(9):2353\u201362. https:\/\/doi.org\/10.1002\/cncr.10494.","journal-title":"Cancer"},{"key":"8044_CR13","doi-asserted-by":"publisher","unstructured":"Hartmann JT, Schmoll HJ, Kuczyk MA, Candelaria M, Bokemeyer C. Postchemotherapy resections of residual masses from metastatic non-seminomatous testicular germ cell tumors. Ann Oncol. 1997;8(6):531\u2013538.\u00a0https:\/\/doi.org\/10.1023\/a:1008200425854","DOI":"10.1023\/a:1008200425854"},{"key":"8044_CR14","doi-asserted-by":"publisher","unstructured":"Aprikian AG, Herr HW, Bajorin DF, Bosl GJ. Resection of postchemotherapy residual masses and limited retroperitoneal lymphadenectomy in patients with metastatic testicular nonseminomatous germ cell tumors. Cancer. 1994;74(4):1329\u201334. https:\/\/doi.org\/10.1002\/1097-0142(19940815)74:4%3C1329::aid-cncr2820740424%3E3.0.co;2-l.","DOI":"10.1002\/1097-0142(19940815)74:4%3C1329::aid-cncr2820740424%3E3.0.co;2-l"},{"key":"8044_CR15","doi-asserted-by":"publisher","unstructured":"Hendry WF, A\u2019Hern RP, Hetherington JW, Peckham MJ, Dearnaley DP, Horwich A. Para-aortic lymphadenectomy after chemotherapy for metastatic non-seminomatous germ cell tumours: prognostic value and therapeutic benefit. Br J Urol. 1993;71(2):208\u201313. https:\/\/doi.org\/10.1111\/j.1464-410x.1993.tb15920.x.","DOI":"10.1111\/j.1464-410x.1993.tb15920.x"},{"key":"8044_CR16","doi-asserted-by":"publisher","unstructured":"Tekgul S et al. Postchemotherapeutic surgery for metastatic testicular germ cell tumors: results of extended primary chemotherapy and limited surgery. Urology. 1994;43(3):349\u2013354.\u00a0 https:\/\/doi.org\/10.1016\/0090-4295(94)90078-7","DOI":"10.1016\/0090-4295(94)90078-7"},{"issue":"10","key":"8044_CR17","doi-asserted-by":"publisher","first-page":"2647","DOI":"10.1200\/JCO.2001.19.10.2647","volume":"19","author":"K Fizazi","year":"2001","unstructured":"Fizazi K, et al. Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: prognostic factors and role of postsurgery chemotherapy\u2013results from an international study group. J Clin Oncol. 2001;19(10):2647\u201357. https:\/\/doi.org\/10.1200\/JCO.2001.19.10.2647.","journal-title":"J Clin Oncol"},{"issue":"2","key":"8044_CR18","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1093\/annonc\/mdm472","volume":"19","author":"K Fizazi","year":"2008","unstructured":"Fizazi K, et al. Assessing prognosis and optimizing treatment in patients with postchemotherapy viable nonseminomatous germ-cell tumors (NSGCT): results of the sCR2 international study. Ann Oncol. 2008;19(2):259\u201364. https:\/\/doi.org\/10.1093\/annonc\/mdm472.","journal-title":"Ann Oncol"},{"issue":"12","key":"8044_CR19","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1097\/MNM.0000000000001093","volume":"40","author":"C Soydal","year":"2019","unstructured":"Soydal C, et al. 18F-Flourodeoxy glucose PET-computed tomography in testicular carcinoma: diagnostic and prognostic value. Nucl Med Commun. 2019;40(12):1268\u201374. https:\/\/doi.org\/10.1097\/MNM.0000000000001093.","journal-title":"Nucl Med Commun"},{"key":"8044_CR20","doi-asserted-by":"publisher","unstructured":"Conduit C et al. Two decades of FDG-PET\/CT in seminoma: exploring its role in diagnosis, surveillance and follow-up. Cancer Imaging 2022;22(1):58.\u00a0 https:\/\/doi.org\/10.1186\/S40644-022-00496-W","DOI":"10.1186\/S40644-022-00496-W"},{"key":"8044_CR21","doi-asserted-by":"crossref","unstructured":"Green DB, La Rosa FG, Craig PG, Khani F, Lam ET. Metastatic Mature Teratoma and Growing Teratoma Syndrome in Patients with Testicular Non-Seminomatous Germ Cell Tumors. 2021;22(10):1650\u20137.","DOI":"10.3348\/kjr.2020.1391"},{"key":"8044_CR22","doi-asserted-by":"publisher","unstructured":"Nalavenkata S, Li T, Patel MI. Nerve-sparing technique in RPLND for testicular cancer. Curr Opin Urol. 2023;281\u20137. https:\/\/doi.org\/10.1097\/MOU.0000000000001100.","DOI":"10.1097\/MOU.0000000000001100"},{"key":"8044_CR23","doi-asserted-by":"publisher","unstructured":"Javadpour N, Kim EE, Deland FH, Salyer JR, Shah U, Goldenberg DM. The Role of Radioimmunodetection in the Management of Testicular Cancer. JAMA. 246(1):45\u201349. https:\/\/doi.org\/10.1001\/JAMA.1981.03320010025023","DOI":"10.1001\/JAMA.1981.03320010025023"},{"issue":"8451","key":"8044_CR24","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/S0140-6736(85)92495-X","volume":"326","author":"AA Epenetos","year":"1985","unstructured":"Epenetos AA, et al. Indium-111 labelled monoclonal antibody to placental alkaline phosphatase in the detection of neoplasms of testis, ovary, and cervix. Lancet. 1985;326(8451):350\u20133. https:\/\/doi.org\/10.1016\/S0140-6736(85)92495-X.","journal-title":"Lancet"},{"issue":"5","key":"8044_CR25","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1053\/ejso.1999.0691","volume":"25","author":"IG Sergides","year":"1999","unstructured":"Sergides IG, Austin RCT, Winslet MC. Radioimmunodetection: Technical problems and methods of improvement. Eur J Surg Oncol. 1999;25(5):529\u201339. https:\/\/doi.org\/10.1053\/ejso.1999.0691.","journal-title":"Eur J Surg Oncol"},{"key":"8044_CR26","doi-asserted-by":"publisher","unstructured":"Pfannenberg C et al. PET\/CT with 18F-FLT: Does it improve the therapeutic management of metastatic germ cell tumors? Journal of Nuclear Medicine.\u00a02010;51(6):845\u2013853. https:\/\/doi.org\/10.2967\/jnumed.109.070425","DOI":"10.2967\/jnumed.109.070425"},{"key":"8044_CR27","doi-asserted-by":"publisher","unstructured":"Shields AF et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat. Med. 1998;4(11):1334\u20136. https:\/\/doi.org\/10.1038\/3337","DOI":"10.1038\/3337"},{"key":"8044_CR28","unstructured":"Buck AK et al. Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG., J. Nucl. Med. 2003;44(9):1426\u201331."},{"key":"8044_CR29","doi-asserted-by":"publisher","unstructured":"Francis DL et al. Potential impact of [18F]3\u2019-deoxy-3\u2019-fluorothymidine versus [18F]fluoro-2-deoxy-D-glucose in positron emission tomography for colorectal cancer. Eur. J. Nucl. Med. Mol. Imaging. 2003;30(7):988\u201394. https:\/\/doi.org\/10.1007\/s00259-003-1187-0","DOI":"10.1007\/s00259-003-1187-0"},{"issue":"5","key":"8044_CR30","doi-asserted-by":"publisher","first-page":"840","DOI":"10.2967\/jnumed.110.087171","volume":"52","author":"F Joly","year":"2011","unstructured":"Joly F, Paciencia M, Bor C, Aide N. Postchemotherapy residual masses in nonseminomatous germ cell tumor patients: 18F-FLT PET is unlikely to identify mature teratoma, but imaging of \u03b1v\u03b23 integrin expression could. J Nucl Med. 2011;52(5):840. https:\/\/doi.org\/10.2967\/jnumed.110.087171.","journal-title":"J Nucl Med"},{"issue":"9","key":"8044_CR31","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/s41568-018-0038-z","volume":"18","author":"H Hamidi","year":"2018","unstructured":"Hamidi H, Ivaska J. Every step of the way: Integrins in cancer progression and metastasis. Nat Rev Cancer. 2018;18(9):533\u201348. https:\/\/doi.org\/10.1038\/s41568-018-0038-z.","journal-title":"Nat Rev Cancer"},{"key":"8044_CR32","doi-asserted-by":"publisher","unstructured":"Hermann P et al. The vitronectin receptor and its associated CD47 molecule mediates proinflammatory cytokine synthesis in human monocytes by interaction with soluble CD23. J. Cell Biol. 1999;144(4):767\u201375. https:\/\/doi.org\/10.1083\/jcb.144.4.767","DOI":"10.1083\/jcb.144.4.767"},{"key":"8044_CR33","doi-asserted-by":"publisher","unstructured":"Hsu AR, Veeravagu A, Cai W, Hou LC, Tse V, Chen X. Integrin alpha v beta 3 antagonists for anti-angiogenic cancer treatment. Recent Pat. Anticancer Drug Discov.\u00a02007;2(2):143\u201358.\u00a0https:\/\/doi.org\/10.2174\/157489207780832469","DOI":"10.2174\/157489207780832469"},{"issue":"6","key":"8044_CR34","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1002\/ddr.20265.Integrin","volume":"69","author":"Z Liu","year":"2008","unstructured":"Liu Z, Wang F, Chen X. Integrin alphaV-beta3-targeted cancer therapy. Drug Dev Res. 2008;69(6):329\u201339. https:\/\/doi.org\/10.1002\/ddr.20265.Integrin.","journal-title":"Drug Dev Res"},{"key":"8044_CR35","doi-asserted-by":"publisher","unstructured":"Weis SM, Cheresh DA. \u03b1V integrins in angiogenesis and cancer. Cold Spring Harb Perspect Med. 2011;1(1):a006478. https:\/\/doi.org\/10.1101\/cshperspect.a006478.","DOI":"10.1101\/cshperspect.a006478"},{"key":"8044_CR36","unstructured":"Andrews PW et al. Pluripotent embryonal carcinoma clones derived from the human teratocarcinoma cell line Tera-2. Differentiation in vivo and in vitro. Lab. Invest. 1984;50(2):147\u201362."},{"key":"8044_CR37","unstructured":"Damjanov I, Horvat B, Gibas Z. Retinoic acid-induced differentiation of the developmentally pluripotent human germ cell tumor-derived cell line, NCCIT. Lab. Invest. 1993;68(2):220\u201332."},{"issue":"2","key":"8044_CR38","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s00259-010-1624-9","volume":"38","author":"N Aide","year":"2011","unstructured":"Aide N, et al. \u03b1v\u03b23 imaging can accurately distinguish between mature teratoma and necrosis in 18F-FDG-negative residual masses after treatment of non-seminomatous testicular cancer: A preclinical study. Eur J Nucl Med Mol Imaging. 2011;38(2):323\u201333. https:\/\/doi.org\/10.1007\/s00259-010-1624-9.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"8044_CR39","doi-asserted-by":"publisher","unstructured":"Kidess M, et al. [18F]F-FAPI-74 PET\/CT for gonadal and extragonadal germ cell Tumors: a pilot study. EJNMMI Res. 2025;16(1). https:\/\/doi.org\/10.1186\/s13550-025-01347-y.","DOI":"10.1186\/s13550-025-01347-y"},{"key":"8044_CR40","doi-asserted-by":"publisher","unstructured":"Woldu SL, et al. Performance characteristics of 18F-fluciclovine positron emission tomography\/computed tomography prior to retroperitoneal lymph node dissection. Can Urol Association J. 2021;16(4). https:\/\/doi.org\/10.5489\/cuaj.7317.","DOI":"10.5489\/cuaj.7317"},{"key":"8044_CR41","unstructured":"Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin. Cancer Res. 1997;3(1):81\u201385."},{"issue":"7","key":"8044_CR42","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.2967\/jnumed.117.203877","volume":"59","author":"DS O\u2019Keefe","year":"2018","unstructured":"O\u2019Keefe DS, Bacich DJ, Huang SS, Heston WDW. A perspective on the evolving story of PSMA biology, PSMA-based imaging, and endoradiotherapeutic strategies. J Nucl Med. 2018;59(7):1007\u201313. https:\/\/doi.org\/10.2967\/jnumed.117.203877.","journal-title":"J Nucl Med"},{"key":"8044_CR43","doi-asserted-by":"publisher","unstructured":"Huang S, et al. Comparison of 18F-based PSMA radiotracers with [68Ga]Ga-PSMA-11 in PET\/CT imaging of prostate cancer\u2014a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2023. https:\/\/doi.org\/10.1038\/s41391-023-00755-2.","DOI":"10.1038\/s41391-023-00755-2"},{"issue":"1","key":"8044_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40644-020-00300-7","volume":"20","author":"F De Galiza","year":"2020","unstructured":"De Galiza F, Barbosa, et al. Nonprostatic diseases on PSMA PET imaging: A spectrum of benign and malignant findings. Cancer Imaging. 2020;20(1):1\u201323. https:\/\/doi.org\/10.1186\/s40644-020-00300-7.","journal-title":"Cancer Imaging"},{"key":"8044_CR45","doi-asserted-by":"publisher","unstructured":"Miceli A, et al. Prostate-Specific Membrane Antigen Positron Emission Tomography Oncological Applications beyond Prostate Cancer in Comparison to Other Radiopharmaceuticals. Diagnostics. 2024;14(10):1002. https:\/\/doi.org\/10.3390\/DIAGNOSTICS14101002.","DOI":"10.3390\/DIAGNOSTICS14101002"},{"key":"8044_CR46","doi-asserted-by":"publisher","unstructured":"Has Simsek D, Civan C, Ekenel M, Kuyumcu S, Sanli Y. 177Lu-PSMA Therapy for Metastatic Testicular Mixed Germ Cell Tumor. Clin Nucl Med. 2021;46(5):415\u20138. https:\/\/doi.org\/10.1097\/RLU.0000000000003563.","DOI":"10.1097\/RLU.0000000000003563"},{"key":"8044_CR47","doi-asserted-by":"publisher","unstructured":"Woldu SL, et al. Performance characteristics of 18F-fluciclovine positron emission tomography\/computed tomography prior to retroperitoneal lymph node dissection. Can Urol Association J. 2021;16(4). https:\/\/doi.org\/10.5489\/cuaj.7317.","DOI":"10.5489\/cuaj.7317"},{"issue":"10","key":"8044_CR48","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1039\/c8md00210j","volume":"9","author":"CL Charron","year":"2018","unstructured":"Charron CL, McFarland MS, Dhanvantari S, Luyt LG. Development of a [68Ga]-ghrelin analogue for PET imaging of the ghrelin receptor (GHS-R1a). Medchemcomm. 2018;9(10):1761\u20137. https:\/\/doi.org\/10.1039\/c8md00210j.","journal-title":"Medchemcomm"},{"issue":"10","key":"8044_CR49","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1039\/c8md00210j","volume":"9","author":"CL Charron","year":"2018","unstructured":"Charron CL, McFarland MS, Dhanvantari S, Luyt LG. Development of a [68Ga]-ghrelin analogue for PET imaging of the ghrelin receptor (GHS-R1a). Medchemcomm. 2018;9(10):1761\u20137. https:\/\/doi.org\/10.1039\/c8md00210j.","journal-title":"Medchemcomm"},{"key":"8044_CR50","doi-asserted-by":"publisher","unstructured":"Kawamura K, et al. Developing new PET tracers to image the growth hormone secretagogue receptor 1a (GHS-R1a). Nucl Med Biol. 2017;52:49\u201356. https:\/\/doi.org\/10.1016\/j.nucmedbio.2017.06.002.","DOI":"10.1016\/j.nucmedbio.2017.06.002"},{"issue":"3","key":"8044_CR51","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1021\/acs.jmedchem.7b01754","volume":"61","author":"J Hou","year":"2018","unstructured":"Hou J, Kovacs MS, Dhanvantari S, Luyt LG. Development of candidates for positron emission tomography (PET) imaging of ghrelin receptor in disease: design, synthesis, and evaluation of fluorine-bearing quinazolinone derivatives. J Med Chem. 2018;61(3):1261\u201375. https:\/\/doi.org\/10.1021\/acs.jmedchem.7b01754.","journal-title":"J Med Chem"},{"issue":"5","key":"8044_CR52","doi-asserted-by":"publisher","first-page":"450","DOI":"10.18632\/oncotarget.27895","volume":"12","author":"R Bergmann","year":"2021","unstructured":"Bergmann R, et al. Development of a ghrelin receptor inverse agonist for positron emission tomography. Oncotarget. 2021;12(5):450\u201374. https:\/\/doi.org\/10.18632\/oncotarget.27895.","journal-title":"Oncotarget"},{"issue":"1","key":"8044_CR53","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1210\/JC.2003-031375","volume":"89","author":"F Gaytan","year":"2004","unstructured":"Gaytan F, et al. Expression of ghrelin and its functional receptor, the type 1a growth hormone secretagogue receptor, in normal human testis and testicular tumors. J Clin Endocrinol Metab. 2004;89(1):400\u20139. https:\/\/doi.org\/10.1210\/JC.2003-031375.","journal-title":"J Clin Endocrinol Metab"},{"key":"8044_CR54","doi-asserted-by":"publisher","unstructured":"Joice GA, Rowe SP, Gorin MA, Pierorazio PM. Molecular Imaging for Evaluation of Viable Testicular Cancer Nodal Metastases. Curr Urol Rep. 2018;19(12). https:\/\/doi.org\/10.1007\/s11934-018-0863-3.","DOI":"10.1007\/s11934-018-0863-3"},{"key":"8044_CR55","doi-asserted-by":"publisher","unstructured":"Childs MD, Luyt LG. A Decade\u2019s Progress in the Development of Molecular Imaging Agents Targeting the Growth Hormone Secretagogue Receptor. SAGE Publications Inc. 2020. https:\/\/doi.org\/10.1177\/1536012120952623.","DOI":"10.1177\/1536012120952623"},{"issue":"10","key":"8044_CR56","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.2967\/JNUMED.124.267578","volume":"65","author":"R Sullivan","year":"2024","unstructured":"Sullivan R, et al. Design, synthesis, and preclinical evaluation of a high-affinity 18F-labeled radioligand for myocardial growth hormone secretagogue receptor before and after myocardial infarction. J Nucl Med. 2024;65(10):1633\u20139. https:\/\/doi.org\/10.2967\/JNUMED.124.267578.","journal-title":"J Nucl Med"},{"key":"8044_CR57","doi-asserted-by":"publisher","unstructured":"Edem PE, Steen EJL, Kj\u00e6r A, Herth MM. Fluorine-18 radiolabeling strategies-advantages and disadvantages of currently applied labeling methods, Late-Stage Fluorination of Bioactive Molecules and Biologically-Relevant Substrates. 2019;29\u2013103. https:\/\/doi.org\/10.1016\/B978-0-12-812958-6.00002-1","DOI":"10.1016\/B978-0-12-812958-6.00002-1"},{"key":"8044_CR58","unstructured":"Claudin 6. Therapeutic prospects for tumours, and mechanisms of expression and regulation (Review). Accessed: May 22, 2025. [Online]. Available: https:\/\/www.spandidos-publications.com\/mmr\/24\/3\/677"},{"key":"8044_CR59","doi-asserted-by":"publisher","unstructured":"Katoh M, Katoh M. Claudin 1, 4, 6 and 18 isoform 2 as targets for the treatment of cancer (Review). Int J Mol Med. 2024;54(5). https:\/\/doi.org\/10.3892\/IJMM.2024.5424.","DOI":"10.3892\/IJMM.2024.5424"},{"issue":"3","key":"8044_CR60","doi-asserted-by":"publisher","first-page":"377","DOI":"10.2967\/JNUMED.124.268487","volume":"66","author":"H Du","year":"2025","unstructured":"Du H, et al. 177Lu-labeled anticlaudin 6 monoclonal antibody for targeted therapy in esophageal cancer. J Nucl Med. 2025;66(3):377\u201384. https:\/\/doi.org\/10.2967\/JNUMED.124.268487.","journal-title":"J Nucl Med"},{"issue":"6","key":"8044_CR61","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1111\/J.1365-2559.2012.04314.X","volume":"61","author":"T Ushiku","year":"2012","unstructured":"Ushiku T, Shinozaki-Ushiku A, Maeda D, Morita S, Fukayama M. Distinct expression pattern of claudin-6, a primitive phenotypic tight junction molecule, in germ cell tumours and visceral carcinomas. Histopathology. 2012;61(6):1043\u201356. https:\/\/doi.org\/10.1111\/J.1365-2559.2012.04314.X.","journal-title":"Histopathology"},{"key":"8044_CR62","doi-asserted-by":"publisher","unstructured":"Adra N et al. A phase II study assessing the safety and efficacy of ASP1650 in male patients with relapsed refractory germ cell tumors. Invest. New Drugs.\u00a02022;40(5):1087\u201394. https:\/\/doi.org\/10.1007\/S10637-022-01276-W.","DOI":"10.1007\/S10637-022-01276-W"},{"key":"8044_CR63","doi-asserted-by":"publisher","unstructured":"McDermott MSJ et al. Preclinical Efficacy of the Antibody-Drug Conjugate CLDN6-23-ADC for the Treatment of CLDN6-Positive Solid Tumors. Clin. Cancer Res.\u00a02023;29(11):2131\u201343. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-2981","DOI":"10.1158\/1078-0432.CCR-22-2981"},{"key":"8044_CR64","doi-asserted-by":"publisher","unstructured":"Mackensen A et al. CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial. Nature Medicine. 2023;29(11):2844\u201353.\u00a0 https:\/\/doi.org\/10.1038\/s41591-023-02612-0","DOI":"10.1038\/s41591-023-02612-0"},{"key":"8044_CR65","doi-asserted-by":"publisher","unstructured":"Sung H, Global Cancer Statistics. 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021;71(3):209\u201349. https:\/\/doi.org\/10.3322\/caac.21660","DOI":"10.3322\/caac.21660"},{"key":"8044_CR66","doi-asserted-by":"publisher","unstructured":"Dotzauer R, Thomas C, J\u00f6ger W. The use of F-FDG PET\/CT in testicular cancer. 2018.\u00a0AME Publishing Company.\u00a0https:\/\/doi.org\/10.21037\/tau.2018.09.08.","DOI":"10.21037\/tau.2018.09.08"},{"key":"8044_CR67","doi-asserted-by":"publisher","unstructured":"Sartor O et al. Lutetium-177\u2013PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. New England Journal of Medicine.\u00a02021:385(12):1091\u2013103. https:\/\/doi.org\/10.1056\/NEJMOA2107322","DOI":"10.1056\/NEJMOA2107322"},{"issue":"6","key":"8044_CR68","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1053\/j.semnuclmed.2025.06.010","volume":"55","author":"A Al-Ibraheem","year":"2025","unstructured":"Al-Ibraheem A, et al. [177Lu]Lu-FAPI radioligand therapy: emerging horizons and clinical promise in solid tumors: a comprehensive review. Semin Nucl Med. 2025;55(6):988\u201398. https:\/\/doi.org\/10.1053\/j.semnuclmed.2025.06.010.","journal-title":"Semin Nucl Med"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-08044-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-026-08044-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-08044-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T08:31:52Z","timestamp":1790929912000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-026-08044-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,2]]},"references-count":68,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["8044"],"URL":"https:\/\/doi.org\/10.1007\/s00259-026-08044-5","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,2]]},"assertion":[{"value":"20 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}